Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Leo Pharma outlines new clinical data transparency policy

Leo Pharma outlines new clinical data transparency policy

24th October 2013

Leo Pharma has declared its support for increased global calls for clinical trial data transparency, confirming that it will be changing its policy on data access from next year.

Effective as of January 1st 2014, researchers, patient associations and healthcare professionals will be granted open access to Leo Pharma's clinical trials data in a way that will not compromise sensitive personal information.

Summary results of trials sponsored by Leo Pharma dating back to 1990 will be posted on the company's corporate website, while reports for approved products will also be gradually made available over a three-year period commencing in March 2014.

Additionally, the company has pledged to ensure that interested parties can receive access on request to anonymised patient-level data for approved products dating back to 2000, with a patient and scientific review board to be established to evaluate these requests.

Gitte Aabo, president and chief executive officer of Leo Pharma, said: "We can enable patients and healthcare professionals to make informed decisions about treatment. We recognise the public health benefits associated with making clinical trials results available."

This comes after the firm announced a new research collaboration with the University of Queensland in the field of skin cancer earlier this month.ADNFCR-8000103-ID-801652957-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.